M&A Deal Summary |
|
|---|---|
| Date | 2019-12-11 |
| Target | Prestwick Chemical |
| Sector | Life Science |
| Buyer(s) | Domain Therapeutics |
| Sellers(s) | Bionomics |
| Deal Type | Divestiture |
SEARCH BY
Domain Therapeutics discovery and development of new medicine for the treatment of chronic neruodegenerative diseases. Domain Therapeutics is based in Illkirch Stratsbourg, France.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 2 of 2 |
| Country: France M&A | 2 of 2 |
| Year: 2019 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-12-11 |
Neurofit SAS
Illkirch-Graffenstaden, France Neurofit SAS is a pre-clinical CRO offering a comprehensive list of disease models and screening assays in the fields of psychiatry, neurology, multiple sclerosis, diabetes, and pain. The company’s core expertise in CNS and PNS includes animal behavior techniques, nerve conduction velocity measure, nerve fiber morphometry, primary neuronal cell cultures. Neurofit has long-standing experiences in psychiatric, neurodegenerative and autoimmune/inflammatory disorders. Our disease models are clinically relevant and predictive. Neurofit was formed in 1996 and is based in Illkirch-Graffenstaden, France. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Revenue | 4M AUD (2019) |
Bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. Bionomics was founded in 1996 and is headquartered in Eastwood ,Australia.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 2 of 2 |
| Country: France M&A | 2 of 2 |
| Year: 2019 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-12-11 |
Neurofit SAS
Illkirch-Graffenstaden, France Neurofit SAS is a pre-clinical CRO offering a comprehensive list of disease models and screening assays in the fields of psychiatry, neurology, multiple sclerosis, diabetes, and pain. The company’s core expertise in CNS and PNS includes animal behavior techniques, nerve conduction velocity measure, nerve fiber morphometry, primary neuronal cell cultures. Neurofit has long-standing experiences in psychiatric, neurodegenerative and autoimmune/inflammatory disorders. Our disease models are clinically relevant and predictive. Neurofit was formed in 1996 and is based in Illkirch-Graffenstaden, France. |
Sell | - |
